Instructions for Gliatilin (choline alfoscerate) 400 mg
Description
Soft gelatin capsules, oval, yellow, opaque; capsule contents - viscous colorless solution.
Description of the drug Gliatilin
ATC Code: N07AX02
Active ingredient:
Choline Alfoscerate
Pharmacotherapeutic group: nootropic agent
Pharmacological effect choline alfoscerate
Central acting cholinomimetics. Choline alfoscerate is a substance that is the precursor of acetylcholine. It affects cholinergic receptors in the central nervous system (CNS).
Contributing to the transmission of nerve impulses Glycerophosphate, which is produced by the breakdown of choline alfoscerate, is involved in the synthesis of phospholipids, which are essential for the normal function of neuronal membranes.
Indications for use Gliatilin
- Craniocerebral injury: Especially with brain stem involvement.
- Chronic cerebrovascular insufficiency: Discirculatory encephalopathy.
- Dementia of various origins: including Alzheimer's disease.
- Ischemic stroke: early and late recovery.
- Gettington's chorea.
- Senile pseudomelancholy.
Method of application and dosage Gliatilin
Oral: 400 mg three times a day.
The course of treatment with the drug is from three to six months.
IM or IV: one gram per day.
Special instructions Gliatilin
Before starting treatment, people should be consulted to determine the indications and exclude contraindications.
- Nosology choline alfoscerate (ICD codes)
- F00
- Dementia Alzheimer's type
- F01
- Vascular dementia
- F03
- Dementia, unspecified
- F07
- Personality and behavior disorders resulting from brain disease, damage, or dysfunction
- G10
- Huntington's chorea
- G93.4
- Encephalopathy, unspecified
- I63
- Brain infarction
- S06
- Intracranial injury
